Alemán revela fármaco de años 60 que mejora la vida en pacientes con linfomaABC.esEl científico ha resumido que el trabajo que él ha coordinado ha servido para comprobar que la bendamustina duplicó la supervivencia libre de enfermedad cuando se a…
BIIB's BG-12 Review Period Extended – Analyst BlogNASDAQMeanwhile, Biogen and partner Abbott Labs ( ABT ) moved another MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010, with results due in 2014. Daclizumab is being e…
BIIB's BG-12 Review Period ExtendedZacks.comMeanwhile, Biogen and partner Abbott Labs (ABT – Analyst Report) moved another MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010, with results due in 2014. Daclizumab is bein…
Economic TimesPipeline Setback at Abbott – Analyst BlogNASDAQOther late-stage candidates at Abbott Labs includes levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson's disease and daclizumab for the treatment of relapsing-remitting multi…
Pipeline Setback at AbbottZacks.comOther late-stage candidates at Abbott Labs includes levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson's disease and daclizumab for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbo…
SCLEROSI MULTIPLA: VICINI AD UNA SVOLTALiberoQuotidiano.itDAC HYP (daclizumab high yeld process): è una terapia sottocutanea mensile, attualmente al centro di studi di fase 3, per il trattamento della SMRR (sclerosi multipla recidivante-remittente). E…
Through 2021, The Number of Disease-Modifying Therapies Approved for The …MarketWatch (press release)However, Decision Resources expects outstanding safety concerns will constrain the adoption of these potentially high-risk/high-reward therapies by a…
Economic TimesEPS Beat for Abbott, Sales Miss – Analyst BlogNASDAQAbbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Results are expected in…
Abbott Laboratories Management Discusses Q3 2012 Results – Earnings Call …Seeking AlphaDaclizumab is our next-generation biologic in development with Biogen for relapsing-remitting multiple sclerosis. Results from 1 of the 2 pivotal trials demonstrat…
Pancreas/Kidney Graft Improves Survival for Type 1 PatientsClinical Endocrinology News Digital NetworkAfter that time, patients receiving a single kidney began to receive basiliximab and the dual-transplant patients got thymoglobulin. The overall 15-ye…